The parasite Entamoeba histolytica is a cause of diarrhea in infants in low-income countries. Previously, it was shown that tumor necrosis factor alpha (TNF-␣) production was associated with increased risk of E. histolytica diarrhea in children. Interleukin-25 (IL-25) is a cytokine that is produced by intestinal epithelial cells that has a role in maintenance of gut barrier function and inhibition of TNF-␣ production. IL-25 expression was decreased in humans and in the mouse model of amebic colitis. Repletion of IL-25 blocked E. histolytica infection and barrier disruption in mice, increased gut eosinophils, and suppressed colonic TNF-␣. Depletion of eosinophils with anti-Siglec-F antibody prevented IL-25-mediated protection. In contrast, depletion of TNF-␣ resulted in resistance to amebic infection. We concluded that IL-25 provides protection from amebiasis, which is dependent upon intestinal eosinophils and suppression of TNF-␣.
IMPORTANCE
The intestinal epithelial barrier is important for protection from intestinal amebiasis. We discovered that the intestinal epithelial cytokine IL-25 was suppressed during amebic colitis in humans and that protection could be restored in the mouse model by IL-25 administration. IL-25 acted via eosinophils and suppressed TNF-␣. This work illustrates a previously unrecognized pathway of innate mucosal immune response.
O
ne of the leading causes of death in children under 5 years of age globally is diarrheal disease. The intestinal parasite Entamoeba histolytica is a common cause of severe diarrhea (1), as recently reaffirmed by two large multicenter studies (2, 3) . While most infections are asymptomatic, up to 20% lead to diarrhea (4) . The varied outcomes of E. histolytica infection are likely due to a combination of parasite, host, and environmental factors (5) .
E. histolytica disrupts the mucosal barrier in a sequential process of adherence to intestinal epithelial cells by a parasite Gal/GalNAc lectin, followed by killing of the epithelial cells in a nibbling process termed amebic trogocytosis, leading to penetration of the epithelium and destruction of underlying tissue (6) (7) (8) . E. histolytica induces several proinflammatory cytokines, including interleukin-1␤ (IL-1␤), IL-23, IL-17, and tumor necrosis factor alpha (TNF-␣) (9) (10) (11) . One of the mechanisms that lead to cytokine production is activation of the inflammasome (12) (13) (14) . While the inflammatory response represents a line of defense, an excessive response may contribute to the tissue damage seen in amebic colitis (15) . High TNF-␣ correlated with diarrhea and disease severity in children infected with E. histolytica, and blocking TNF-␣ with neutralizing monoclonal antibody (MAb) was shown to reduce inflammation and intestinal damage (16) (17) (18) . TNF-␣ induces macrophages and neutrophils to produce reactive oxygen species and nitric oxide to kill E. histolytica; however, oxygen free radicals may also be responsible for collateral tissue damage (15) .
Epithelial tuft cells in the bowel produce the cytokine IL-25, which has multiple functions (19) . TNF-␣ negatively regulates IL-25 production in the human gut (20) . IL-25 can activate both innate and adaptive sources to induce type 2 cytokines, such as IL-4, IL-5, IL-9, and IL-13 (21) . Commensal gut bacteria increase IL-25 production by epithelial intestinal cells (22) . IL-25 is also a potent inducer of the antimicrobial peptide angiogenin-4 in an IL-13-dependent manner (23) . IL-25 induces eosinophil infiltration in the gut (24) , which is potentially relevant in amebiasis as eosinophilia was also associated with reduced size and number of amebic liver abscesses in the gerbil model (25) . However, the role of IL-25 in amebic colitis remains unknown.
Here, we demonstrate that the anti-inflammatory cytokine IL-25 is suppressed during E. histolytica infection in humans and in a mouse model of amebic colitis. We tested the role of IL-25 by administering recombinant IL-25 (rIL-25) to mice during amebic colitis and discovered that IL-25 protected against amebic colitis and that this protection was eosinophil dependent and acted in part by suppressing TNF-␣.
RESULTS
IL-25 is suppressed during E. histolytica infection in humans and in the mouse model. Because of the importance of the microbiome and the intestinal epithelium in defense against E. histolytica colitis (26) (27) (28) , we hypothesized that IL-25 would be protective against amebic infection in the cecum. Human colon biopsy samples from controls (from the University of Virginia) and amebic colitis patients were stained for IL-25 by immunohistochemistry. IL-25 was less abundant in amebic colitis patients ( Fig. 1A and B) .
We utilized the mouse model of amebic colitis to test the importance of IL-25 in defense against E. histolytica invasion. CBA/J mice were challenged with E. histolytica and compared to control mice that received a sham challenge. IL-25 was decreased at day 1 and day 2 in both groups but remained depressed after day 3 only in the E. histolytica-challenged mice. Sham-challenged mice returned to baseline levels of IL-25 after day 3 (Fig. 1C ). Mice that cleared E. histolytica infection had a non-statistically significant higher level of IL-25 ( Fig. 1C , solid blue circles) than mice that remained infected (solid red circles). We concluded that IL-25 was reduced with E. histolytica infection both in humans and in the mouse model.
IL-25 had a protective role against E. histolytica colitis in the mouse model. In order to test whether IL-25 would protect mice against amebiasis, we injected into the peritoneum 0.5 g of rIL-25 or phosphate-buffered saline (PBS) daily for 4 days prior to and 4 days after E. histolytica challenge. E. histolytica infection and parasite burden in the cecum were decreased in the rIL-25-treated group ( Fig. 2A to C) . Epithelial disruption was reduced in the rIL-25-treated group at 7 days after E. histolytica challenge ( Fig. 2D and E). We concluded that IL-25 reduced E. histolytica burden and maintained the gut barrier.
rIL-25 administration induced type 2 responses. IL-25 regulates type 2 immunity in the gut via type 2 innate lymphoid cells (21) . In order to describe the immune response induced by IL-25 during amebiasis, we measured IL-4, IL-5, and IL-9 by enzyme-linked immunosorbent assay (ELISA) from cecal tissue lysates of mice after E. histolytica challenge with or without rIL-25 treatment. We found that IL-4 and IL-5 were elevated in rIL-25-treated mice ( Fig. 3A and B) , whereas IL-9 was not (Fig. 3C) . Inducible nitric oxide synthase-encoding mRNA (Nos2) was decreased in the presence of rIL-25 (Fig. 3D) . On the other hand, the amount of mRNA encoding chitinase 3-like 1 (Chi3l1) and eosinophil peroxidase (Epx) was upregulated in the presence of rIL-25 ( Fig. 3E and F) . These data suggested that rIL-25 induces alternatively activated macrophages during E. histolytica infection. We also measured inflammatory cytokines known to be suppressed by IL-25: IL-23, IL-17, and TNF-␣. These cytokines as expected were decreased in the cecal tissue lysate of rIL-25-treated mice (Fig. 3G to I ).
Eosinophils were important for IL-25-mediated protection. IL-25 is known to increase eosinophils in the gut, and IL-25-induced eosinophilia protects against pathogenesis in Clostridium difficile colitis (24) . Increased gut eosinophil peroxidase (Epx) mRNA with IL-25 suggested that eosinophils could be important for protection against amebic colitis (Fig. 3F) . Increased eosinophils in the lamina propria during amebic infection were detected by flow cytometry (Fig. 4A) . We tested the importance of eosinophils in protection against amebic colitis by depletion with anti-Siglec-F. AntiSiglec-F monoclonal antibody or an IgG2a isotype control antibody was administered to IL-25-treated mice. Depletion of eosinophils abrogated IL-25 protection (Fig. 4B and C) and decreased gut IL-4 (Fig. 4D) , as expected since eosinophils are a major source of IL-4 (29). These findings indicated that eosinophils were required for IL-25-mediated protection. IL-25-mediated protection was accompanied by decreased TNF-␣ in the mouse model. rIL-25-treated mice contained lower levels of E. histolytica on days 4 and 7 after E. histolytica challenge (Fig. 5A) . TNF-␣ was decreased on both day 4 and day 7 in the presence of rIL-25 (Fig. 5B) .
TNF-␣ is upregulated during amebic colitis in humans, and anti-TNF-␣ treatment protected mice from amebiasis. TNF-␣ was measured in colon biopsy samples collected from amebic colitis and control patients by immunohistochemistry (Fig. 6A) . TNF-␣ protein was higher in amebic colitis patients as assessed by immunohistochemistry (Fig. 6B) . From these results, we hypothesized that suppression of TNF-␣ expression was a possible mechanism by which IL-25 mediates protection against amebiasis. To test this, TNF-␣ was neutralized by use of a monoclonal antibody in CBA/J mice. There was a lower infection rate (Fig. 6C ) and lower antigen load (Fig. 6D ) in mice treated with anti-TNF-␣ antibody. IL-25 suppression of TNF-␣ could be one potential mechanism of the protective action of IL-25. 
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DISCUSSION
The most important finding of our study is that the intestinal epithelial cytokine IL-25 protects against amebic colitis. IL-25 was suppressed in the colon of humans with amebic colitis and in the murine model, and repletion of IL-25 reduced E. histolytica infection and protected the gut epithelial barrier. IL-25 provided protection from amebic colitis in an eosinophil-dependent process, as demonstrated by abrogation of protection by depletion of eosinophils with antiSiglec-F. Siglec-F is a cell surface lectin belonging to the Ig superfamily that binds glycol conjugates containing sialic acids that are commonly found on eosinophils in mice, although it was also reported that various cell types, such as alveolar macrophages and intestinal M cells, express this surface protein (30, 31) . Recently, Buonomo et al. have reported that IL-25 also is protective against Clostridium difficile infection through eosinophil induction (24) . Additionally, C. difficile infection with strains containing CDT (Clostridium difficile transferase toxin) causes more severe pathology because they suppress the accumulation of eosinophils in the lamina propria of the colon (32) . For C. difficile infection, IL-25 acted by reducing host inflammation but not pathogen burden, whereas for amebic colitis, both pathogen burden and inflammation were suppressed. Therefore, there may be differences in how eosinophils act to protect from amebiasis and C. difficile.
The role of eosinophils in amebiasis has not been studied intensively (33) . Induction of eosinophils by use of Toxocara canis antigen resulted in reduced amebic liver abscess size and number in an animal model. Also supporting a role for eosinophils in amebiasis is the observation that degenerated eosinophil products (Charcot-Leiden crystals) are present along with trophozoites in the stool of patients with amebiasis (34) .
We hypothesized that an IL-25-induced influx of eosinophils would ultimately function to suppress gut inflammation to provide protection against amebic colitis. We expected that IL-25-mediated protection in amebiasis would be associated with a shift from a proinflammatory response to type 2 immunity. In this context, we found that rIL-25 administration in mice in fact suppressed expression of inflammatory cytokines (IL-23, IL-17, and TNF-␣) and induced type 2 cytokines (IL-4 and IL-5).
The proinflammatory cytokine TNF-␣ is known to play a crucial role in intestinal inflammation during amebic colitis (16) . We reported here that TNF-␣ in human colon biopsy specimens was elevated during amebic colitis and that administration of rIL-25 decreased TNF-␣ in the mouse model during amebic colitis. Furthermore, TNF-␣ depletion rendered mice resistant to E. histolytica infection. This was of particular import, as amebic diarrhea is positively correlated with TNF-␣ production in humans (17) . Considered together, TNF-␣ suppression by eosinophils is a possible mechanism of IL-25-mediated protection, although the detailed interaction between TNF-␣ and IL-25 has not been studied in the present study.
IL-25 induction of alternatively activated macrophages could be a mechanism of TNF-␣ suppression. Eosinophils are known as a major source of IL-4 that induces macrophage polarization into anti-inflammatory macrophages (35) . In our study, we found that IL-25 induction of IL-4 was blocked when eosinophils were depleted with monoclonal antibodies. IL-25 administration caused downregulation of nitric oxide synthase 2 (Nos2) and upregulation of chitinase 3-like 1 (Chi3l1), a transcript present in type 2 alternatively activated macrophages.
Although it has not been studied whether IL-25 acts directly on eosinophils, direct stimulation by IL-25 may be possible as the IL-25 receptor IL-25RB has been reported to be expressed on human eosinophils (36) . It also has not been investigated whether eosinophil-induced IL-4 can cause macrophage polarization to suppress TNF-␣. Further investigation is required to understand the cellular and molecular mechanism of the IL-25-eosinophil pathway during amebiasis. The hypothesis that IL-25 acts to protect from amebiasis through eosinophil conversion of type 1 to type 2 macrophages therefore remains to be tested.
In conclusion, we have found that IL-25 is suppressed during amebic colitis and that administration of IL-25 in a mouse model reduced E. histolytica trophozoite number, antigen load, and epithelial disruption in the cecum. Moreover, we demonstrated that eosinophils induced by IL-25 may protect by suppressing TNF-␣, as IL-25 suppressed TNF-␣ levels and neutralization of TNF-␣ prevented amebic colitis.
scored. The staining scale was between 0 and 5. The percentage of the visual field that had intense brown staining within one or two villi was scored. There were two different fields randomly chosen from each sample.
Statistical analysis. Student's t test or the Mann-Whitney U nonparametric test was used for comparisons between two groups. P values of less than 0.05 were considered significant. Statistical analysis was performed using GraphPad Prism (GraphPad Software, Inc., San Diego, CA). All experiments are representative of at least three independent replicates.
